GenVec, Inc. (Nasdaq:GNVC) presented an overview of TNFerade” development and an update on long-term survival data from its Phase II clinical trial using TNFerade in patients with esophageal cancer at the American Society of Gene Therapy (ASGT) 11th Annual Meeting in Boston, MA. Dr.